PARIS (Reuters) – U.S. drugs giant Pfizer and vaccine company Valneva have decided to end trials on a significant percentage of participants in the United States who had been used as the companies work on a vaccine product to tackle Lyme disease.
Pfizer and Valneva said in a joint statement on Friday that they were ending those trials due to “violations of Good Clinical Practice (GCP) at certain clinical trial sites run by a third-party clinical trial site operator.”
“The discontinuation of these participants was not due to any safety concerns with the investigational vaccine and was not prompted by a participant-reported adverse event,” Pfizer and Valneva said in their statement.
(Reporting by Sudip Kar-GuptaEditing by Jacqueline Wong)
